This study is currently recruiting.
Description: This is a 2-part study, with each part having a unique set of objectives for male adolescents aged 12 to < 18 years with fragile X syndrome (FXS). Part 1 is an open-label, single-dose, pharmacokinetics (PK) assessment of BPN14770 25 mg and 50 mg, while Part 2 is double-blind (DB) and randomized between two treatment groups (Study Drug and Placebo).
Eligibility & Criteria
IRB #: 000312157
Principal Investigator: Dejan Budimirovic, MD
Eligible Age Range: 12-18 years of ager
Gender: All
Diagnosis: Fragile X Syndrome